PP60 C-SRC IN GROWTH TRANSFORMATION & DIFFERENTIATION
增长转型中的 PP60 C-SRC
基本信息
- 批准号:3186166
- 负责人:
- 金额:$ 10.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-01-01 至 1991-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adenoviridae Rous sarcoma virus X ray crystallography affinity chromatography antibody formation autoradiography cell differentiation cell growth regulation cell transformation enzyme linked immunosorbent assay fluorescence microscopy gel electrophoresis gene expression gene mutation genetic library genetic manipulation immunofluorescence technique immunoprecipitation laboratory mouse molecular biology nucleic acid hybridization oncogenes phosphates plasmids point mutation protein biosynthesis protein structure protein tyrosine kinase virus protein
项目摘要
pp60c-src is the cellular homolog of pp60v-src, the transforming protein of
Rous Sarcoma Virus. The protein is located on the cytoplasmic face of the
plasma membrane and is believed to function in signal transduction in
response to mitogens and other extracellular signals including PDGF, NGF
and, perhaps, CSF-1. The experiments proposed here make use of recently
developed recombinant DNA techniques and address two different, but
related, questions concerning the molecular biology of pp60c-src. The
first set of experiments examines structure-function relationships in the
protein. Eukaryotic viral vectors will be used to obtain milligram
quantities of the protein. The purified pp60c-src should facilitate a
number of experiments - we propose using it first to prepare monoclonal
antibodies and to search for kinases and phosphatases believed to modify
the activity of the molecule as a tyrosine kinase. To complement these
biochemical studies we will construct a large library of mutant c-src genes
using a recombinant murine retrovirus which we have recently constructed
and the so-called GC clamp technique from the Manjatis laboratory. The
second set of experiments are designed to follow up our recent finding that
the level of pp60c-src is modulated some 20-fold during the differentiation
of monocytes. We have designed experiments to discover if specific
receptors are interacting with pp60c-src in the fully differentiated cells
and to see if pp60c-src might also play a role in the differentiation
process itself.
Pp60c-src是pp60v-src的细胞同源物
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS M ROBERTS其他文献
THOMAS M ROBERTS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS M ROBERTS', 18)}}的其他基金
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
9816457 - 财政年份:2019
- 资助金额:
$ 10.29万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10238853 - 财政年份:2019
- 资助金额:
$ 10.29万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
9978752 - 财政年份:2019
- 资助金额:
$ 10.29万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10705059 - 财政年份:2019
- 资助金额:
$ 10.29万 - 项目类别:
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
最大化 PI3K 抑制剂治疗 Pten 无效癌症的有效性
- 批准号:
10468110 - 财政年份:2019
- 资助金额:
$ 10.29万 - 项目类别:
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway
项目 2:通过 PP2A/YAP/Hippo 途径进行致癌转化
- 批准号:
10227783 - 财政年份:2017
- 资助金额:
$ 10.29万 - 项目类别:
PROJECT 2: Oncogenic Transformation via the PP2A/YAP/Hippo pathway
项目 2:通过 PP2A/YAP/Hippo 途径进行致癌转化
- 批准号:
9981671 - 财政年份:2017
- 资助金额:
$ 10.29万 - 项目类别:
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer
克服乳腺癌标准 HER2 导向疗法的耐药性
- 批准号:
8607754 - 财政年份:2013
- 资助金额:
$ 10.29万 - 项目类别:
The Role of Bub1 in SV40 Large T Mediated Transformation
Bub1 在 SV40 大 T 介导的转化中的作用
- 批准号:
8233029 - 财政年份:2011
- 资助金额:
$ 10.29万 - 项目类别:
相似海外基金
CRYSTALLOGRAPHY OF N TERMINAL DOMAIN OF ROUS SARCOMA VIRUS CAPSID PROTEIN: HIV
劳斯肉瘤病毒衣壳蛋白 N 末端结构域的晶体学:HIV
- 批准号:
6483466 - 财政年份:2001
- 资助金额:
$ 10.29万 - 项目类别:
CRYSTALLOGRAPHY OF N TERMINAL DOMAIN OF ROUS SARCOMA VIRUS CAPSID PROTEIN: HIV
劳斯肉瘤病毒衣壳蛋白 N 末端结构域的晶体学:HIV
- 批准号:
6339290 - 财政年份:2000
- 资助金额:
$ 10.29万 - 项目类别:
CRYSTALLOGRAPHY OF N TERMINAL DOMAIN OF ROUS SARCOMA VIRUS CAPSID PROTEIN: HIV
劳斯肉瘤病毒衣壳蛋白 N 末端结构域的晶体学:HIV
- 批准号:
6315670 - 财政年份:1999
- 资助金额:
$ 10.29万 - 项目类别:
CRYSTAL STRUCTURE OF CATALYTIC CORE FRAGMENT OF ROUS SARCOMA VIRUS INTEGRASE
劳斯肉瘤病毒整合酶催化核心片段的晶体结构
- 批准号:
6120546 - 财政年份:1998
- 资助金额:
$ 10.29万 - 项目类别:
RNA Signaling Control in Rous Sarcoma Virus
劳斯肉瘤病毒中的 RNA 信号传导控制
- 批准号:
6951420 - 财政年份:1998
- 资助金额:
$ 10.29万 - 项目类别:














{{item.name}}会员




